Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left">Daily dose of SPRM</td><td align="center">Number of patients</td><td align="center">Mean AI (±SD)</td><td align="center">Median of AI</td><td align="center">Range of AI</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left">Ulipristal 5 mg</td><td align="center">6</td><td align="center">231.8 (±237.8)</td><td align="center">181</td><td align="center">26–672</td></tr><tr><td align="left">Ulipristal 10 mg</td><td align="center">5</td><td align="center">71.4 (±71.2)</td><td align="center">81</td><td align="center">0–173</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>AI: apoptotic index, SD: standard deviation, and SPRM: selective progesterone receptor modulator.<br/></td></tr></table>

Dependence of the number of apoptotic cells on the dose of SPRM.

International Journal of Endocrinology

tab3

Table 3

Table 3: Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo 